Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Avalanche Treasury Corporation Class A Common Stock (AVAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Avalanche Treasury Corporation Class A Common Stock — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Avalanche Treasury Corporation Class A Common Stock trades at $0.34 (market cap $15.33M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 1930.9× Avalanche Treasury Corporation Class A Common Stock's market cap. Which is the better fit depends on your goals.
| ALNY | AVAT | |
|---|---|---|
Market Cap | $29.60B | $15.33M |
Sector | Health | Financials |
52-Week High | $491.22 | $10.75 |
52-Week Low | $205.48 | $0.30 |
Enterprise Value | $27.56B | $15.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
AVAT trades at $0.3426, up 1.75% today, with a bearish technical signal from moving averages and a P/E of 12. The company reported net income of $8.28 million for 2025, but negative operating cash flow of $930,710 raises concerns about liquidity. Recent news highlights its Nasdaq listing as Avalanche Treasury Co., focusing on capital allocation within its ecosystem.
The outlook is mixed: profitability and low valuation offer potential upside, but cash flow challenges and bearish technicals present risks. Investor sentiment is cautious due to operational losses, though the public listing may attract institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →
